- NewLink reports impressive survival data for HyperAcute cancer vaccines
- MARQUEE collapses on tivantinib in NSCLC but other uses offer hope
- Merck KGaA withdraws Erbitux NSCLC filing
- ImmunoGen seeks conjugate bliss as T-DM1 anticipation builds
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.